Key statistics
On Friday, Halozyme Therapeutics Inc (RV7:FRA) closed at 55.64, -4.37% below its 52-week high of 58.18, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.96 |
---|---|
High | 55.96 |
Low | 53.96 |
Bid | 55.52 |
Offer | 55.64 |
Previous close | 55.70 |
Average volume | 959.90 |
---|---|
Shares outstanding | 127.23m |
Free float | 125.85m |
P/E (TTM) | 19.29 |
Market cap | 7.42bn USD |
EPS (TTM) | 3.02 USD |
Data delayed at least 15 minutes, as of Feb 14 2025 17:35 GMT.
More ▼
Press releases
- Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
- CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
- Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
- Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
- Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
- Halozyme to Present at Upcoming Investor Conferences
- Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
More ▼